12:00 AM
 | 
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BEMA Buprenorphine/Naloxone: Pivotal trial completed enrollment

BioDelivery Sciences completed enrollment in the 2-way crossover, pivotal BNX-103 trial comparing BEMA Buprenorphine/Naloxone to sublingual Suboxone Buprenorphine/Naloxone in healthy volunteers. In February, BioDelivery said it reached an agreement with FDA on the development program for BEMA Buprenorphine/Naloxone,...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >